NCT05726851View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

January 30, 2024

Study Completion Date

January 30, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

E2025

E2025 IV infusion.

DRUG

Placebo

E2025 matched placebo IV infusion.

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY